13.17
Wpływ choroby wątroby na farmakokinetykę: ocena patofizjologiczna i próby wątrobowe
View the full transcript and gain access to JoVE Core videos
Q1: Why can't clinicians directly measure hepatic blood flow to assess liver function?
Direct measurement of hepatic blood flow requires specialized techniques that are often impractical in clinical settings. Instead, clinicians estimate hepatic function through patient examination and liver function tests, which provide more accessible and reliable information for assessing drug metabolism and clearance in patients with liver disease.
Q2: What do the Child-Pugh and MELD scores tell us about drug pharmacokinetics?
While the Child-Pugh and MELD scoring systems effectively categorize hepatic impairment severity, they do not directly correlate with drug pharmacokinetics. These scores assess liver function but don't reliably predict how drugs will be metabolized or cleared in hepatically impaired patients, necessitating additional assessment for dosing decisions.
Q3: How do elevated AST and ALT ratios help diagnose liver disease?
Elevated AST/ALT ratios indicate acute liver injury, alcoholic hepatitis, or advanced liver fibrosis. These aminotransferase markers provide valuable insights into hepatic function and the liver's capacity to metabolize drugs, helping clinicians assess the degree of hepatic impairment and adjust medication dosing accordingly.
Q4: What does increased alkaline phosphatase suggest about liver health?
Increased alkaline phosphatase levels may indicate hepatic tumors or biliary obstruction, signaling potential compromise in liver function. This marker helps clinicians identify structural or metabolic abnormalities affecting the liver's ability to clear drugs and maintain functional capacity in patients requiring medication adjustments.
Q5: How do prothrombin time and urinary bilirubin levels differ in assessing hepatic disease?
Prothrombin time deviations signal hepatic failure or biliary obstruction by reflecting the liver's synthetic function, while variations in urinary bilirubin levels help diagnose hepatobiliary disease. Together, these markers provide complementary information about liver dysfunction and guide effect of hepatic disease on pharmacokinetics dose adjustments due to hepatic impairment.
Q6: Why does chronic liver disease require different dosing approaches than acute hepatitis?
Chronic liver disease significantly compromises drug metabolism and clearance, requiring systematic dosing adjustments. Acute hepatitis causes more nuanced metabolic changes, necessitating case-by-case assessment. Both conditions demand tailored risk evaluation before dosing, though establishing standardized guidelines for hepatically impaired patients remains an evolving area of clinical practice.
Q7: What role do liver function tests play in medication management for hepatic impairment?
Liver function tests measuring aminotransferases, alkaline phosphatase, bilirubin, and prothrombin time provide critical insights into hepatic function and drug clearance capacity. These markers enable clinicians to make informed decisions about tailored therapeutic interventions and medication adjustments, ensuring safe and effective treatment in patients with hepatic disease.